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LIVER BIOPSY: IMPORTANCE OF SPECIMEN SIZE IN THE DIAGNOSIS AND STAGING OF CHRONIC 
VIRAL HEPATITIS
Gabriela P. CORAL(1), Aline Dal Pozzo ANTUNES(1), Ana Paula Almeida SERAFINI(1) Fernanda B. ARAUJO(2) & Angelo Alves de MATTOS(1)
SUMMARY
Liver biopsy is the gold standard method for the grading and staging of chronic viral hepatitis, but optimal biopsy specimen size 
remains controversial. The aim of this study was to evaluate the quality of liver specimen (number of portal tracts) and to evaluate the 
impact of the number of portal tracts in the staging of chronic hepatitis. Material and Methods: 468 liver biopsies from consecutive 
patients with hepatitis C virus and hepatitis B virus infection from 2009 to 2010 were evaluated. Results: The length of fragment 
was less than 10 mm in 43 cases (9.3%), between 10 and 14 mm in 114 (24.3%), and ≥ 15 mm in 311 (64.4%); of these, in 39 (8.3%) 
cases were ≥ 20 mm. The mean representation of portal tracts was 17.6 ± 2.1 (5-40); in specimens ≥ 15 mm the mean portal tract 
was 13.5 ± 4.7 and in cases ≤ 15 mm was 11.4 ± 5.0 (p = 0.002). Cases with less than 11 portal tracts were associated with F3, and 
cases with 11 or more portal tracts with F2 (p = 0.001). Conclusion: this study demonstrated the good quality of liver biopsy and a 
relationship between the macroscopic size of the fragment and the number of portal tracts. 
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INTRODUCTION
The emergence of hepatology as a defined clinical medical specialty 
is coincident with the introduction of liver biopsy and Menghini’s needle 
in 19581. Clinical hepatologists were trained in liver pathology and 
were responsible for the foundation of the main schools of hepatology 
in Europe and United States2. In the past, the only way to diagnose liver 
disease was by liver biopsy.
Grading and staging chronic hepatitis are essential for assessing 
prognosis and deciding which patients should be given priority for 
treatment3. Liver biopsy is also helpful to rule out other diagnoses and to 
evaluate steatosis and iron4. Although biopsy is an invasive procedure, the 
risk of major complications is very low (0.22-0.75%)5,6. The mortality rate 
attributed to the procedure is estimated in one per 10 thousand biopsies 
and is usually secondary to bleeding; this is even lower when the biopsy 
is not performed for evaluation of liver tumors7,8.
Recently, noninvasive methods were developed to assess liver 
fibrosis9. In this setting, measure of liver stiffness by elastography is 
widely used for selection of patients eligible for drug therapy3. However, 
liver biopsy remains the gold standard and the most used method in our 
setting10. In a recent study that evaluated 1,202 patients with chronic 
hepatitis C virus (HCV), elastography showed false positive results in 
patients with high levels of aminotransferases and obesity11. Usually, a 
body mass index (BMI) greater than 28 results in failure of liver stiffness 
measurement12. Moreover, fibroscan is a diagnostic test that depends on 
the experience of the operator13. Recent meta-analysis demonstrated 83% 
of sensitivity and 89% of specificity for the diagnosis of cirrhosis by 
elastography. On the other hand, in patients with moderate fibrosis, (F2 
of METAVIR) sensitivity was 79% and specificity 78%14. It’s noteworthy 
that the guidelines for hepatitis C treatment of the AASLD (American 
Association for the Study of Liver Diseases) and the EASL (European 
Association for the Study of the Liver) accepted noninvasive methods 
for therapeutic decision3,15. 
Liver biopsy is subjected to sampling error, since a standard specimen 
represents only about 0.0002% of the whole liver. Then, it is essential 
that the sample be representative for limiting the risk of inappropriate 
results, but optimal biopsy specimen size remains controversial9,16,17,18.
Therefore, the aim of this study was to evaluate the quality of liver 
specimen [number of portal tracts (PT)], to correlate the sample size with 
the number of PT and to evaluate the impact of the number of PT in the 
staging of chronic viral hepatitis. 
MATERIALS AND METHODS
Liver biopsies from consecutive patients with HCV and HBV 
infection from 2009 to 2010 were included in this study conducted 
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in a tertiary hospital in southern Brazil (Irmandade Santa Casa de 
Misericórdia de Porto Alegre-ISCMPA).
Patients under the age of 18 were excluded, as well as those with 
other causes of chronic liver disease.
All biopsies were guided by ultrasonography using an 18 G 
disposable Tru-Cut needle. The specimens were fixed in 10% formalin 
and evaluated with respect to size (mm). When two or more fragments 
were obtained, the larger was analyzed. Fragmentation of the specimen 
was also assessed. Samples were classified as ≥ 15 mm and < 15 mm 
for statistical analysis.
Liver biopsies were routinely stained with Hematoxylin-
eosin, Perls and Masson’s trichrome, and evaluated by the same 
hepatopathologist who was blinded to the size of specimen and clinical 
data. The number of PT was evaluated in all cases, excepted in those 
with cirrhosis, because of changes in liver architecture, annulling 
the individualization of PT19. Specimens with less than five PT 
were considered inadequate for analysis20. Biopsies were classified 
according to METAVIR score21.
This study was approved by the Institutional Review Board of 
ISCMPA.
Statistical analysis was performed using SPSS software (Statistical 
Package for Social Sciences) version 17.0. Quantitative variables were 
described using mean and standard deviation (symmetrical distribution) 
or median (asymmetric distribution). Categorical variables were 
described by absolute and relative frequencies. The Chi-square and 
Pearson, Fisher’s exact test and One Way analysis of variance test were 
used for statistical analysis. A p value ≤ 0.05 was considered statistically 
significant. 
RESULTS
Four hundred and sixty-eight liver biopsies were evaluated. The mean 
age of patients was 57.7 years (18-78). Two hundred and thirty-eight 
patients were female (50.8%).
Fragment size was less than 10 mm in 43 cases (9.3%), range between 
10 and 14 mm in 114 (24.3%), and was ≥ 15 mm in 311 (64.4%); of 
these, in 39 (8.3%) cases were ≥ 20 mm. The mean length of fragments 
was 13.3 ± 4.2 mm. The fragmented specimens were 21/468 (4.5%), 
and in these cases the report pointed out the possible limitation of the 
staging performed.
Of the 468 cases, 39 (8.3%) had a diagnosis of liver cirrhosis; 
therefore, the specimens considered for assessment of number of PT 
was 429. The mean representation of PT per biopsy was 17.6 ± 2.1 (5-
40) and the median was 15. Moreover, in specimens ≥ 15 mm the mean 
PT was 13.5 ± 4.7, and in cases < 15 mm it was 11.4 ± 5.0 (p = 0.002). 
The number of PT per sample was as follows: 5 PT in 20 cases (4.7%), 
6 to 8 in 88 cases (20.6%), 9 to 10 in 67 cases (15.5%), and ≥ 11 PT in 
254 (59.3%). 
Fibrosis stage was scored as follows: F0 in 67 patients (14.3%), 
F1 in 192 (41.0%), F2 in 114 (24.4%), F3 in 56 (12.0%), and F4 in 39 
(8.3%). The necroinflammatory activity was classified as absent (A0) in 
32 cases (6.8%), mild (A1) in 215 cases (45.5%), moderate (A2) in 185 
(39.1%), and severe (A3) in 36 (7.6%). Steatosis was present in 41.6% 
and iron in 20.5%.
The association between fibrosis staging and the number of PT 
is shown in Table 1. There was a statistically significant difference 
indicating that the mean of PT in samples with F2 (13.7 ± 4.4) was 
significantly higher when compared to other stages (F0: 11.5 ± 4.6 – p 
< 0.01; F1: 11.9 ± 5.2 – p < 0.05; F3: 11.0 ± 4.9 – p < 0.001). 
There was a significant association between fibrosis stage F3 and 
representation of less than 11 PT, and an association between F2 and 11 
or more PT (p = 0.001) (Table 2).
Table 1
Portal tracts according fibrosis staging
Fibrosis
Number of EP
N Mean Std Deviation Median10.50 Minimum Maximum
F0 67 11.48 4.56 11.00 5 23
F1 192 11.90 5.18 13.00 5 40
F2 114 13.70 4.46 10.00 5 24
F3 56 11.04 1.93 5 23
One way analysis of variance-(F2
calc = 5.366; p = 0.001)
Table 2
Fibrosis staging according portal tracts: stratified sample
Fibrosis Portal Tracts Total
< 11 ≥ 11
F0 32 (18.5%) 32 (12.6%) 64 (15%)
F1 81 (46.8%) 111 (43.9%) 192 (45.1%)
F2 30 (17.3%) 84 (33.2%) 114 (26.8%)
F3 30 (17.3%) 26 (10.3%) 56 (13.1%)
Total 173 (100%) 253 (100%) 426 (100%)
Chi-square and Pearson (p = 0.001)
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DISCUSSION
Liver biopsy is a diagnostic method widely used for staging of chronic 
hepatitis, despite the rising of noninvasive methods. However, one of its 
limitations is sampling variability. In order to minimize sampling error, 
biopsy needs to be representative of the whole liver7.
The size considered ideal for histological analysis is under debate 
in the literature22. Some studies suggest that a biopsy of 10-15 mm in 
length, with 4-6 PT is sufficient for staging of chronic hepatitis17,18,23 
whereas, other authors suggest a minimum size of 20 to 25 mm and at 
least 11 PT9,16.
SCHIANO et al.18 analyzed 100 biopsies and didn’t find a significant 
difference in fibrosis stage when evaluating different sizes of the same 
liver specimen. Ninety-four per cent of the specimens of 10 mm received 
the same staging or just one degree of difference when compared with the 
20 mm. On the other hand, COLLOREDO et al.9 studied 161 biopsies 
from patients with chronic hepatitis considering only specimens of 30 
mm or more. These fragments were first examined in their original size 
and then reduced in size to be reanalyzed (20 mm, 15 mm and 10 mm). 
The necroinflammatory activity and fibrosis were more often considered 
as discrete when smaller size was analyzed. A sample larger than or 
equal to 20 mm and representation of at least 11 full PT was considered 
necessary for accurate evaluation.
BEDOSSA et al.16 also compared the results of staging the same 
biopsy in two different sizes: 25 mm and 15 mm. In agreement with the 
previous study, they demonstrated that larger fragments allowed to assess 
staging more accurately.
In the present study, in 90.7% cases the fragment had more than 10 
mm, the minimum size recommended by BEDOSSA et al., in the study 
that validated the METAVIR classification21. Similarly, in this study, the 
average number of PT was 17.6 and the median was 15, demonstrating 
a good quality of liver biopsy. 
Importantly, a systematic review evaluating the quality of liver 
biopsies demonstrated that the mean PT represented was 7.5 ± 3.4 
in 10,027 biopsies. In this systematic review, the correlation between 
fragment size and number of PT was low (Spearman r = 0:45)22. In this 
study, we found a correlation between PT and size of fragment.
In the present study, 40.7% of the sample had less than 11 PT. 
However, it was shown that advanced fibrosis (F3) was even linked to 
the representation of less than 11 PT. Thus, although it has been shown 
that 11 PT would be ideal minimum number for staging9,16, this study 
is consistent with other studies that suggest that less than 11 PT may 
be suitable17,18,23.
Regarding the liver biopsy sample size , attention should be drawn 
to the fact that the vast majority of clinical trials in chronic hepatitis did 
not mention the number of PT represented22,24. 
We conclude that liver biopsy in real life, in a general hospital, has 
good quality, showing in almost all cases, the minimum size suggested 
for the diagnosis and staging. A relationship between the macroscopic 
size of the fragment and the number of PT represented has also been 
demonstrated. Furthermore, in this study, representation of less than 11 
and more than 5 PT probably did not adversely influence the staging.
Abbreviations: 
PT- Portal tracts
HCV - Hepatitis C virus
BMI- Body Mass Index
AASLD- American Association for the Study of Liver Diseases 
EASL- European Association for the Study of the Liver
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